Nutritional Supplement

Flavonoids

  • Negative Interactions

    13
    • Flavonoids

      Anastrozole

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin, found primarily in the peel of citrus fruits, interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Anastrozole
      Flavonoids
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Diethylstilbestrol

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Diethylstilbestrol
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Quercetin

      Estradiol

      Potential Negative Interaction

      Studies have shown that grapefruit juice significantly increases estradiol levels in the blood. One of the flavonoids found in grapefruit juice is quercetin. In a test tube study, quercetin was found to change estrogen metabolism in human liver cells in a way that increases estradiol levels and reduces other forms of estrogen. This effect is likely to increase estrogen activity in the body. However, the levels of quercetin used to alter estrogen metabolism in the test tube were much higher than levels found in the body after supplementing with quercetin.

      There is evidence from test tube studies that another flavonoid in grapefruit juice, naringenin, also has estrogenic activity. It has yet to be shown that dietary or supplemental levels of quercetin (or naringenin) could create a significant problem.

      Estradiol
      Quercetin
      ×
      1. Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 1994;20:155-63.
      2. Weber A, Jager R, Borner A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996;53:41-7.
      3. Schubert W, Eriksson U, Edgar B, et al. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur J Drug Metab Pharmacokinet 1995;3:219-24.
      4. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-63.
    • Tangeretin

      Estramustine

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Estramustine
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Quercetin

      Felodipine

      Potential Negative Interaction

      Quercetin is a flavonoid found in grapefruit juice, tea, onions, and other foods; it is also available as a nutritional supplement. Quercetin has been shown in test tube studies to inhibit enzymes responsible for breaking down felodipine into an inactive form. This interaction may result in increased blood levels of felodipine that could lead to unwanted side effects. Until more is known about this interaction, patients taking felodipine should avoid supplementing with quercetin.

      Felodipine
      Quercetin
      ×
      1. Miniscalco A, Lundahl J, Regardh CG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992;261:1195-9.
    • Tangeretin

      Leuprolide

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Leuprolide
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Megestrol

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Megestrol
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Nilutamide

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Nilutamide
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Tamoxifen

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Tamoxifen
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Testolactone

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Testolactone
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Toremifene

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Toremifene
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Triptorelin Pamoate

      Potential Negative Interaction

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Triptorelin Pamoate
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
    • Tangeretin

      Bicalutamide

      Reduces Effectiveness

      Preliminary research in animals found that the citrus flavonoid tangeretin (found primarily in the peel of citrus fruits) interferes with the ability of tamoxifen to inhibit tumor growth. Although the evidence is far from conclusive, people taking tamoxifen should probably avoid citrus bioflavonoid supplements, as well as beverages and foods to which citrus peel oils have been added.

      Bicalutamide
      Tangeretin
      ×
      1. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999;91:354-9.
  • Supportive Interactions

    1
    • Flavonoids

      Acyclovir

      Support Medicine

      The flavonoids quercetin, quercitrin, and apigenin enhanced the antiviral activity of acyclovir in test tube studies. Controlled research is needed to determine whether taking quercetin or other flavonoid supplements would increase the effectiveness of acyclovir in humans.

      Acyclovir
      Flavonoids
      ×
      1. Mucsi I, Gyulai Z, Beladi I. Combined effects of flavonoids and acyclovir against herpesviruses in cell cultures. Acta Microbiol Hung 1992;39:137-47.
  • Explanation Required

    1
    • Quercetin

      Cyclosporine

      Needs Explanation

      In an animal study, oral administration of quercetin (50 mg per 2.2 pounds of body weight) at the same time as cyclosporine decreased the absorption of cyclosporine by 43%. However, in a study of healthy human volunteers, supplementing with quercetin along with cyclosporine significantly increased blood levels of cyclosporine, when compared with administering cyclosporine alone. Because the effect of quercetin supplementation on cyclosporine absorption or utilization appears to be unpredictable, individuals taking cyclosporine should not take quercetin without the supervision of a doctor.

      Cyclosporine
      Quercetin
      ×
      1. Hsiu SL, Hou YC, Wang YH, et al. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 2002;72:227-35.
      2. Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm 2004;61:2406-9.

References

1. Peterson J, Dwyer J. Taxonomic classification helps identify flavonoid-containing foods on a semiquantitative food frequency questionnaire. J Am Diet Assoc 1998;98:682-5.

2. Holden M, Molloy E. Further experiments on the inactivation of herpes virus by vitamin C (l-ascorbic acid). J Immunol 1937;33:251-7.

3. Terezhalmy GT, Bottomley WK, Pelleu GB. The use of water-soluble bioflavonoid-ascorbic acid complex in the treatment of recurrent herpes labialis. Oral Surg 1978;45:56-62.

4. Vaananen MK, Markkanen HA, Tuovinen VJ, et al. Periodontal health related to plasma ascorbic acid. Proc Finn Dent Soc 1993;89:51-9.

5. Aurer-Kozelj J, Kralj-Klobucar N, Buzina R, Bacic M. The effect of ascorbic acid supplementation on periodontal tissue ultrastructure in subjects with progressive periodontitis. Int J Vitam Nutr Res 1982;52:333-41.

6. Woolfe SN, Kenney EB, Hume WR, Carranza FA Jr. Relationship of ascorbic acid levels of blood and gingival tissue with response to periodontal therapy. J Clin Periodontol 1984;11:159-65.

7. Vogel RI, Lamster IB, Wechsler SA, et al. The effects of megadoses of ascorbic acid on PMN chemotaxis and experimental gingivitis. J Periodontol 1986;57:472-9.

8. El-Ashiry GM, Ringsdorf WM, Cheraskin E. Local and systemic influences in periodontal disease. II. Effect of prophylaxis and natural versus synthetic vitamin C upon gingivitis. J Periodontol 1964;35:250-9.

9. Carvel I, Halperin V. Therapeutic effect of water soluble bioflavonoids in gingival inflammatory conditions. Oral Surg Oral Med Oral Pathol 1961;14:847-55.

10. Vaananen MK, Markkanen HA, Tuovinen VJ, et al. Periodontal health related to plasma ascorbic acid. Proc Finn Dent Soc 1993;89:51-9.

11. Aurer-Kozelj J, Kralj-Klobucar N, Buzina R, Bacic M. The effect of ascorbic acid supplementation on periodontal tissue ultrastructure in subjects with progressive periodontitis. Int J Vitam Nutr Res 1982;52:333-41.

12. Woolfe SN, Kenney EB, Hume WR, Carranza FA Jr. Relationship of ascorbic acid levels of blood and gingival tissue with response to periodontal therapy. J Clin Periodontol 1984;11:159-65.

13. Vogel RI, Lamster IB, Wechsler SA, et al. The effects of megadoses of ascorbic acid on PMN chemotaxis and experimental gingivitis. J Periodontol 1986;57:472-9.

14. El-Ashiry GM, Ringsdorf WM, Cheraskin E. Local and systemic influences in periodontal disease. II. Effect of prophylaxis and natural versus synthetic vitamin C upon gingivitis. J Periodontol 1964;35:250-9.

15. Carvel I, Halperin V. Therapeutic effect of water soluble bioflavonoids in gingival inflammatory conditions. Oral Surg Oral Med Oral Pathol 1961;14:847-55.

16. Sinnatamby CS. The treatment of hemorrhoids. Role of hydroxyethylrutosides, troxerutin (Paroven; Varmoid; Venoruton). Clin Trials J 1973;2:45-50.

17. Clyne MB, Freeling P, Ginsborg S. Troxerutin in the treatment of haemorrhoids. Practitioner 1967;198:420-3.

18. Annoni F, Boccasanta P, Chiurazzi D, et al. Treatment of acute symptoms of hemorrhoid disease with high-dose oral O-(beta-hydroxyethyl)-rutosides. Minerva Med 1986;77:1663-8 [in Italian].

19. Wijayanegara H, Mose JC, Achmad L, et al. A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy. J Int Med Res 1992;20:54-60.

20. Thorp RH, Hughes ESR. A clinical trial of trihydroxyethylrutoside (“Varemoid”) in the treatment of hemorrhoids. Med J Aust 1970;2:1076-8.

21. Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57:145-51.

22. Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73.

23. Thanapongsathorn W, Vajrabukka T. Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids. Dis Colon Rectum 1992;35:1085-8.

24. Schorah CJ, Tormey WP, Brooks GH, et al. The effect of vitamin C supplements on body weight, serum proteins, and general health of an elderly population. Am J Clin Nutr 1981;34:871-6.

25. Shamrai EF. Vitamin P. Its chemical nature and mechanism of physiologic action. Uspekhi Sovremennoi Biologii 1968;65:186-201.

26. Horoschak A. Nocturnal leg cramps, easy bruisability and epistaxis in menopausal patients: treated with hesperidin and ascorbic acid. Delaware State Med J 1959;Jan:19-22.

27. Reinhold U, Seiter S, Ugurel S, Tilgen W. Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients. J Am Acad Dermatol 1999;41:207-8.

28. Ohguro H, Ohguro I, Katai M, Tanaka S. Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma. Ophthalmologica 2012;228:26–35.

29. Varma SD. Inhibition of aldose reductase by flavonoids: Possible attenuation of diabetic complications. Progr Clin Biol Res 1986;213:343-58.

30. Glacet-Bernard A, Coscas G, Chabanel A, et al. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421-9.

31. Holden M, Molloy E. Further experiments on the inactivation of herpes virus by vitamin C (l-ascorbic acid). J Immunol 1937;33:251-7.

32. Terezhalmy GT, Bottomley WK, Pelleu GB. The use of water-soluble bioflavonoid-ascorbic acid complex in the treatment of recurrent herpes labialis. Oral Surg 1978;45:56-62.

33. CJ Smith. Non-hormonal control of vaso-motor flushing in menopausal patients. Chicago Med 1964;67:193-5.

34. Cohen JD, Rubin HW. Functional menorrhagia: treatment with bioflavonoids and vitamin C. Curr Ther ResClin Exp 1960;2:539-42.

35. Mukherjee GG, Gajaraj AJ, Mathias J, Marya D. Treatment of abnormal uterine bleeding with micronized flavonoids. Int J Gynaecol Obstet2005;89:156-7.

36. Johnston CS, Retrum KR, Srilakshmi JC. Antihistamine effects and complications of supplemental vitamin C. J Am Diet Assoc 1992;92:988-9.

37. Johnston S, Martin LJ, Cai X. Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis. J Am Coll Nutr 1992;11:172-6.

38. Gabor M. Anti-inflammatory and anti-allergic properties of flavonoids. Prog Clin Biol Res 1986;213:471-80 [review].

39. Middleton E, Drzewieki G. Naturally occurring flavonoids and human basophil histamine release. Int Arch Allergy Appl Immunol 1985;77:155-7.

40. Amella M, Bronner C, Briancon F, et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica 1985;51:16-20.

41. CJ Smith. Non-hormonal control of vaso-motor flushing in menopausal patients. Chicago Med 1964;67:193-5.

42. Rehn D, Brunnauer H, Diebschlag W, Lehmacher W. Investigation of the therapeutic equivalence of different galenical preparations of O-(s-hydroxyethyl)-rutosides following multiple dose per oral administration. Arzneimittelforschung 1996;46:488-92.

43. Bergqvist D, Hallbook T, Lindblad B, Lindhagen A. A double-blind trial of O-(s-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa 1981;10:253-60.

44. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994;23:244-50.

45. Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung 1996;46:478-82.

46. Neumann HA, van den Broek MJ. A comparative clinical trial of graduated compression stockings and O-(beta-hydroxyethyl)-rutosides (HR) in the treatment of patients with chronic venous insufficiency. Z Lymphol 1995;19:8-11.

47. Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000;51:197-205 [review].

48. Sohn C, Jahnichen C, Bastert G. [Effectiveness of beta-hydroxyethylrutoside in patients with varicose veins in pregnancy]. Zentralbl Gynakol 1995;117:190-7 [in German].

49. Schlebusch H, Kern D. Stabilization of collagen by polyphenols. Angiologica 1972;9:248-56 [in German].

50. Monboisse J, Braquet P, Randoux A, Borel J. Non-enzymatic degradation of acid-soluble calf skin collagen by superoxide ion: protective effect of flavonoids. Biochem Pharmacol 1983;32:53-8.

51. Lagrue G, Olivier-Martin F, Grillot A. A study of the effects of procyanidol oligomers on capillary resistance in hypertension and in certain nephropathies. Sem Hop 1981;57:1399-401 [in French].

52. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993;12:69-72.

53. Bruneton J. Pharmacognosy Phytochemistry Medicinal Plants. Andover: Intercept Ltd., 1995, 277.

54. Varma SD. Inhibition of aldose reductase by flavonoids: Possible attenuation of diabetic complications. Progr Clin Biol Res 1986;213:343-58.

55. Glacet-Bernard A, Coscas G, Chabanel A, et al. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421-9.

56. Cohen JD, Rubin HW. Functional menorrhagia: treatment with bioflavonoids and vitamin C. Curr Ther ResClin Exp 1960;2:539-42.

57. Mukherjee GG, Gajaraj AJ, Mathias J, Marya D. Treatment of abnormal uterine bleeding with micronized flavonoids. Int J Gynaecol Obstet2005;89:156-7.

58. Moser M, Ranacher G, Wilmot TJ, Golden GJ. A double-blind clinical trial of hydroxyethylrutosides in Meniere's disease. J Laryngol Otol 1984;98:265-72.

59. Franklin DJ, Pollak A, Fisch U. Meniere's symptoms resulting from bilateral otosclerotic occlusion of the endolymphatic duct: an analysis of a causal relationship between otosclerosis and Meniere's disease. Am J Otol 1990;11:135-40.

60. Liston SL, Paparella MM, Mancini F, Anderson JH. Otosclerosis and endolymphatic hydrops. Laryngoscope 1984;94:1003-7.

61. Freeman J. Otosclerosis and vestibular dysfunction. Laryngoscope 1980;90:1481-7.

62. Sismanis A, Hughes GB, Abedi E. Coexisting otosclerosis and Meniere's disease: a diagnostic and therapeutic dilemma. Laryngoscope 1986;96:9-13.

63. Brookler KH, Glenn MB. Meniere's syndrome: an approach to therapy. Ear Nose Throat J 1995;74:534-8, 540, 542.

64. Bretlau P, Hansen HJ, Causse J, Causse JB. Otospongiosis: morphologic and microchemical investigation after NaF-treatment. Otolaryngol Head Neck Surg 1981;89:646-50.

65. Causse JR, Causse JB, Uriel J, et al. Sodium fluoride therapy. Am J Otol 1993;14:482-90 [review].

66. Lin YM, Flavin MT, Schure R, et al. Antiviral activities of bioflavonoids. Planta Med 1999;65:120-5.

67. Bar-Meir S, Halpern Z, Gutman M, et al. Effect of (+)-cyanidanol-3 on chronic active hepatitis: A double blind controlled trial. Gut 1985;26:975-9.

68. Conn HO. Cyanidanol: will a hepatotrophic drug from Europe go west? Hepatology 1983;3:121-3.

69. Pamukcu AM, Yalciner S, Hatcher JF, Bryan GT. Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (Pteridium aquilinum). Cancer Res 1980;40:3468-72.

70. Hirono I, Ueno I, Hosaka S, et al. Carcinogenicity examination of quercetin and rutin in ACI rats. Cancer Lett 1981;13:15-21.

71. Saito D, Shirai A, Matsushima T, et al. Test of carcinogenicity of quercetin, a widely distributed mutagen in food. Teratog Carcinog Mutagen 1980;1:213-21.

72. Aeschbacher H-U, Meier H, Ruch E. Nonmutagenicity in vivo of the food flavonol quercetin. Nutr Cancer 1982;2:90.

73. Nishino H, Nishino A, Iwashima A, et al. Quercetin inhibits the action of 12-O-tetradecanoylphorbol-13-acetate, a tumor promoter. Oncology 1984;41:120-3.

74. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 1996;110:41-8.

75. Knekt P, Jarvinen R, Seppanen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997;146:223-30.

76. Hertog M, Feskens EJM, Hollman PCH, et al. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. Nutr Cancer 1994;22:175-84.

77. Stavric B. Quercetin in our diet: from potent mutagen to probable anticarcinogen. Clin Biochem 1994;27:245-8.

Copyright © 2024 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2024.

Log In

You need to log into the site to use this feature

Create A Free Account To Use Medicine Chest

This feature requires registration. Sign up or log in to your free WellRx account to gain access to this and other tools to help make managing your medications and wellness easier.

Benefits Include:

Store & manage your medication list
Medication pricing updates
Import medication from your pharmacy
Medication information
Pill & refill reminders
Medication journal & mood log

Sign up to use Medicine Chest

Create A Free Account To Use this feature

This feature requires registration. Sign up or log in to your free WellRx account to gain access to this and other tools to help make managing your medications and wellness easier.

Benefits Include:

Store & manage your medication list
Medication pricing updates
Import medication from your pharmacy
Medication information
Pill & refill reminders
Medication journal & mood log

Sign up to use this feature

You will be redirected to your program in 5 seconds.

Hi there.

Our Terms and Conditions and Privacy Policy have recently been updated.

Learn More


I Accept

By declining you will be logged out of your account

;